Ibuprofen Lysinate and Sodium Ibuprofen for Prophylaxis of Patent Ductus Arteriosus in Preterm Neonates.
Indian Pediatr
;
2012 January; 49(1): 47-49
Article
in English
| IMSEAR
| ID: sea-169076
ABSTRACT
This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age 28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P=0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P=0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Type of study:
Observational study
Language:
English
Journal:
Indian Pediatr
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS